Key Laboratory for Pharmaceutical Quality Control of Hebei Province, College of Pharmaceutical Sciences, Hebei University, Wusi East Road No. 180, Baoding, Hebei 071002, China; Key Laboratory of Medical Chemistry and Molecular Diagnosis, Ministry of Education, Wusi East Road No. 180, Baoding, Hebei 071002, China.
Bioorg Med Chem. 2013 Dec 15;21(24):7624-7. doi: 10.1016/j.bmc.2013.10.034. Epub 2013 Nov 6.
In an effort to develop potent anti-cancer chemopreventive agents that act on topoisomerase II, a novel series of bisindolylalkanes analogues such as 3,3'-(thiochroman-4,4-diyl)bis(1H-indole) are synthesized. Structures of all compounds are elucidated by (1)H NMR, (13)C NMR and HRMS. Anti-proliferative activities for all of these compounds are investigated by the method of MTT assay on 7 human cancer lines. Most of them showed antitumor activities in vitro, the half maximal inhibitory concentration (IC50) value is 7.798 μg/mL of 3a against MCF7. Compound 3a showed comparable topoisomerase II inhibitory activity to etoposide (VP-16) at 100 μM concentration. The rest of the compounds also showed varying degree topoisomerase II inhibitory activity.
为了开发作用于拓扑异构酶 II 的强效抗癌化学预防剂,合成了一系列新型双茚基烷类似物,如 3,3'-(硫代色满-4,4-二基)双(1H-吲哚)。所有化合物的结构均通过 (1)H NMR、(13)C NMR 和 HRMS 进行阐明。通过 MTT 法在 7 个人类癌细胞系上测定所有这些化合物的抗增殖活性。它们中的大多数在体外表现出抗肿瘤活性,IC50 值为 3a 对 MCF7 的 7.798μg/mL。化合物 3a 在 100μM 浓度下表现出与依托泊苷 (VP-16) 相当的拓扑异构酶 II 抑制活性。其余的化合物也表现出不同程度的拓扑异构酶 II 抑制活性。